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Summary
Background Guidelines for primary prevention of cardiovascular diseases focus on prediction of coronary heart 
disease and stroke. We assessed whether or not measurement of N-terminal-pro-B-type natriuretic peptide (NT-
proBNP) concentration could enable a more integrated approach than at present by predicting heart failure and 
enhancing coronary heart disease and stroke risk assessment.
Methods In this individual-participant-data meta-analysis, we generated and harmonised individual-participant data 
from relevant prospective studies via both de-novo NT-proBNP concentration measurement of stored samples and 
collection of data from studies identiﬁ ed through a systematic search of the literature (PubMed, Scientiﬁ c Citation Index 
Expanded, and Embase) for articles published up to Sept 4, 2014, using search terms related to natriuretic peptide family 
members and the primary outcomes, with no language restrictions. We calculated risk ratios and measures of risk 
discrimination and reclassiﬁ cation across predicted 10 year risk categories (ie, <5%, 5% to <7·5%, and ≥7·5%), adding 
assessment of NT-proBNP concentration to that of conventional risk factors (ie, age, sex, smoking status, systolic blood 
pressure, history of diabetes, and total and HDL cholesterol concentrations). Primary outcomes were the combination of 
coronary heart disease and stroke, and the combination of coronary heart disease, stroke, and heart failure.
Findings We recorded 5500 coronary heart disease, 4002 stroke, and 2212 heart failure outcomes among 95 617 participants 
without a history of cardiovascular disease in 40 prospective studies. Risk ratios (for a comparison of the top third vs 
bottom third of NT-proBNP concentrations, adjusted for conventional risk factors) were 1·76 (95% CI 1·56–1·98) for 
the combination of coronary heart disease and stroke and 2·00 (1·77–2·26) for the combination of coronary heart 
disease, stroke, and heart failure. Addition of information about NT-proBNP concentration to a model containing 
conventional risk factors was associated with a C-index increase of 0·012 (0·010–0·014) and a net reclassiﬁ cation 
improvement of 0·027 (0·019–0·036) for the combination of coronary heart disease and stroke and a C-index increase 
of 0·019 (0·016–0·022) and a net reclassiﬁ cation improvement of 0·028 (0·019–0·038) for the combination of coronary 
heart disease, stroke, and heart failure.
Interpretation In people without baseline cardiovascular disease, NT-proBNP concentration assessment strongly 
predicted ﬁ rst-onset heart failure and augmented coronary heart disease and stroke prediction, suggesting that 
NT-proBNP concentration assessment could be used to integrate heart failure into cardiovascular disease 
primary prevention.
Funding British Heart Foundation, Austrian Science Fund, UK Medical Research Council, National Institute for 
Health Research, European Research Council, and European Commission Framework Programme 7.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license. 
Introduction
Cardiovascular disease guidelines recommend strategies 
that predict and prevent composite endpoints for 
coronary heart disease and stroke.1–4 A rationale for this 
combined approach is to enhance eﬃ  ciency of 
cardiovascular disease screening by capitalising on 
shared risk factors and preventive interventions, even 
though coronary heart disease and stroke are 
aetiologically distinct. Such a rationale could be extended 
to heart failure. The age-speciﬁ c incidence of heart 
failure is increasing; it is a common initial presentation 
of cardiovascular disease.5 Furthermore, statins and 
antihypertensive treatments might, in addition to their 
beneﬁ ts for primary prevention of coronary heart disease 
and stroke, be eﬀ ective at reducing the risk of new-onset 
heart failure.6,7 Practical advantages of a strategy that 
integrates heart failure prediction into cardiovascular 
disease risk assessment could exist since coronary heart 
disease and stroke risk assessment is already widespread, 
whereas primary prevention of heart failure is not 
addressed by current guidelines.8,9
One approach that could enable such an integrated 
strategy is measurement of soluble natriuretic peptides. 
These molecules play important roles in regulation 
of blood pressure, blood volume, and sodium balance.10 
Assessment of circulating B-type natriuretic peptide 
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concentration and its more stable by-product N-terminal-
pro-B-type natriuretic peptide (NT-proBNP) is recom-
mended by guidelines for diagnosis and management of 
patients with heart failure.8,9 As natriuretic peptides are 
markers of vascular remodelling, their measurement 
could also serve as an adjunct in prediction of ﬁ rst-ever 
coronary heart disease and stroke outcomes.11 However, to 
what extent assessment of natriuretic peptides can predict 
ﬁ rst-onset heart failure outcomes or improve prediction 
of coronary heart disease and stroke in people without 
known cardiovascular disease is uncertain.12–16 To address 
these questions, we established the Natriuretic Peptides 
Studies Collaboration, an inter national consortium of 
individual-participant data from individuals without a 
history of cardiovascular disease at baseline.
Methods
Data sources 
Using two complementary approaches, we generated, 
collated, and harmonised individual-participant-level data 
from relevant prospective cohorts. First, de-novo 
NT-proBNP concentration measurements of stored sam-
ples were done by technicians masked to case-control 
status for some studies using the Elecsys2010 electro-
chemiluminescence method (proBNP Generation II; 
Roche, Burgess Hill, UK; appendix p 4). Second, we 
sought individual-participant data from relevant pro-
spective studies identiﬁ ed through systematic searches of 
the published literature (PubMed, Scientiﬁ c Citation 
Index Expanded, and Embase) for articles published up to 
Sept 4, 2014, using search terms related to natriuretic 
peptide family members and the primary outcomes, with 
no language restrictions (appendix p 7). We also scanned 
reference lists of identiﬁ ed articles for additional relevant 
studies. Studies were eligible if they had assayed NT-
proBNP or B-type natriuretic peptide (BNP) concentration; 
recorded baseline information about age, sex, smoking 
status, systolic blood pressure, history of diabetes, and 
total and HDL cholesterol concentration (conventional 
risk factors); included participants without a known 
history of cardiovascular disease (ie, coronary heart 
disease, stroke, transient ischaemic attack, peripheral 
vascular disease, cardiovascular surgery, pulmonary heart 
disease, atrial ﬁ brillation, or heart failure) at entry into the 
study; and recorded cause-speciﬁ c deaths or major 
cardiovascular morbidity (non-fatal myocardial infarction, 
stroke, or heart failure) using well deﬁ ned criteria over at 
least 1 year of follow-up.
The appendix (p 4) provides details of the methods used 
to collect and harmonise data. Contributing studies 
classiﬁ ed deaths according to the primary cause (or, in 
its absence, the underlying cause) on the basis of 
International Classiﬁ cation of Diseases coding, 
revisions 8–10, to at least three digits, or according to 
study-speciﬁ c classiﬁ cation systems. We based ascer-
tainment of fatal outcomes on death certiﬁ cates, 
Research in context
Evidence before this study
We hypothesised that integrated cardiovascular disease risk 
assessment strategies could be extended to primary prevention 
of heart failure through measurement of N-terminal-pro-B-type 
natriuretic peptide (NT-proBNP) concentration. In a systematic 
review of the published literature (searches of PubMed, 
Scientiﬁ c Citation Index Expanded, and Embase for relevant 
articles published up to Sept 4, 2014, using search terms related 
to natriuretic peptide family members and the primary 
outcomes, with no language restrictions), we identiﬁ ed 
33 relevant prospective studies of natriuretic peptides and 
incident coronary heart disease, stroke, or heart failure 
outcomes. We attempted a synthesis of these results in a 
previous literature-based review, but we found that using 
published results was insuﬃ  ciently powered or detailed or both 
to enable reliable assessment of whether or not NT-proBNP 
concentration measurement could augment cardiovascular 
disease risk assessment for coronary heart disease and stroke, 
and investigators of only few population-based prospective 
studies reported on associations between NT-proBNP 
concentration and ﬁ rst-onset heart failure.
Added value of this study
The Natriuretic Peptides Studies Collaboration involved new 
NT-proBNP concentration measurements in eight 
prospective studies as well as collation and harmonisation of 
individual-participant data from a further 32 relevant 
prospective cohorts identiﬁ ed by an updated systematic review. 
This eﬀ ort enabled a detailed and standardised analysis of 
primary data for 95 617 participants without a history of 
cardiovascular disease recruited into 40 prospective studies in 
12 diﬀ erent countries. The key added value of this collaboration 
is its ability to derive valid and new insights by combination of 
individual-participant data, information about various 
established and emerging risk factors, extended follow-up, 
breadth of cardiovascular disease outcomes recorded (eg, fatal 
and non-fatal heart failure, coronary heart disease, and stroke), 
study of several diﬀ erent measures of predictive ability, and 
generalisability to several high-income industrialised countries.
Implications of all the available evidence
We found that NT-proBNP concentration assessment strongly 
predicted ﬁ rst-onset heart failure and augmented coronary heart 
disease and stroke prediction. The incremental predictive ability 
of NT-proBNP concentration for coronary heart disease and 
stroke was moderate, but still greater than were those for HDL 
cholesterol or C-reactive protein concentrations. Our results have 
suggested that NT-proBNP concentration assessment could serve 
as a multipurpose biomarker in new approaches that integrate 
heart failure into cardiovascular disease primary prevention. 
See Online for appendix
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supplemented in 26 cohorts by additional data, and of 
non-fatal outcomes on WHO (or similar) criteria for 
myocardial infarction and on clinical and imaging features 
for stroke and heart failure (appendix p 18). This Article 
follows Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses for Individual Patient Data reporting 
(appendix pp 8–11).17 The study was designed and done by 
the Natriuretic Peptides Studies Collaboration’s 
independent coordinating centre and approved by the 
Cambridgeshire Ethics Review Committee.
Data analysis
The analysis involved three inter-related components. 
First, we characterised cross-sectional associations of 
NT-proBNP concentration with established and emerging 
risk factors. Second, we assessed associations of 
NT-proBNP concentration with ﬁ rst-onset coronary 
heart disease, stroke, and heart failure, singly and in 
combination. Third, we quantiﬁ ed the incremental 
predictive value of assessment of NT-proBNP con-
centration in addition to conventional risk factors for 
major cardiovascular disease outcomes. 
We focused the principal analyses on NT-proBNP 
concentration data because NT-proBNP is a more stable 
analyte than is BNP and encompassed more than 95% of 
the data in the collaboration (reserving the sparse BNP 
data for supplementary analyses). We deﬁ ned two 
primary outcomes: 1) a combination of coronary heart 
disease (deﬁ ned as fatal or non-fatal myocardial 
infarction) and stroke and 2) a combination of coronary 
heart disease, stroke, and heart failure. Participants 
contributed only the ﬁ rst cardiovascular disease outcome 
(whether non-fatal or fatal) recorded during follow-up (ie, 
we did not include deaths preceded by non-fatal 
cardiovascular disease events). Secondary outcomes were 
the component cardiovascular disease outcomes (ie, 
coronary heart disease, stroke, and heart failure) and the 
aggregate of death due to additional cardiovascular 
disease outcomes (ie, cardiac arrhythmia, hypertensive 
disease, pulmonary embolism, complications and ill 
deﬁ ned descriptions of heart disease, sudden death, 
aortic aneurysms, and peripheral vascular disease). We 
censored outcomes if a participant was lost to follow-up, 
died from causes other than cardiovascular diseases, or 
reached the end of the follow-up period.
We calculated hazard ratios from prospective studies 
with Cox proportional hazard regression models, stratiﬁ ed 
by sex, using time-on-study as a timescale. We assessed the 
proportional hazards assumption, which was satisﬁ ed, as 
previously described.18 Analyses of case-cohort data 
involved Prentice weights and robust SEs.19 We calculated 
odds ratios from nested case-control studies using logistic 
regression models. We assumed hazard and odds ratios to 
represent the same relative risk, collectively describing 
them as risk ratios. We calculated risk ratios for a 
comparison of individuals in the top third with those in the 
bottom third of baseline NT-proBNP values using a 
two-stage approach, with estimates calculated separately 
within each study before pooling across studies with 
multivariate random-eﬀ ects meta-analysis.18 To characterise 
shapes of associations, we calculated pooled risk ratios 
within overall tenths of NT-proBNP concentration and 
plotted them against the pooled geometric mean of NT-
proBNP concentration within each tenth. We adjusted risk 
ratios for baseline levels of conventional risk factors. We 
investigated eﬀ ect modiﬁ cation by study-level and 
individual characteristics with meta-regression and formal 
tests of interaction.18 We assessed between-study 
heterogeneity with the I² statistic.20
We developed cardiovascular disease risk prediction 
models containing information about conventional risk 
factors with or without NT-proBNP concentration only 
in cohort and case-cohort studies and quantiﬁ ed 
improvements in predictive ability using measures of 
risk discrimination and reclassiﬁ cation.21,22 We calculated 
C-indices and C-index changes within each study before 
pooling results weighted by the number of outcomes 
contributed. We calculated measures of risk reclassiﬁ -
cation (ie, integrated discrimination improvement and 
categorical and continuous net reclassiﬁ cation improve-
ment) using data from studies in which both fatal and 
non-fatal events had been recorded.21 We examined 
categorical net reclassiﬁ cation of participants across 
predicted 10 year risk categories using cutoﬀ s deﬁ ned by 
the American College of Cardiology (ACC) and American 
Heart Association (AHA) 2013 (ie, <5%, 5% to <7·5%, 
and ≥7·5%),1 National Institute of Health and Care 
Excellence 2014,4 American College of Cardiology 
Foundation and American Heart Association 2010,3 and 
European Society of Cardiology 2016 guidelines.2 We log-
transformed NT-proBNP concentration and modelled it 
using both linear and quadratic terms (with similar 
approaches used for the analysis of HDL cholesterol and 
C-reactive protein [CRP] concentration). We did analyses 
using Stata software, version 12.1. All p values are two 
sided. The appendix (pp 5–6) provides further details of 
the analytical methods used.
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. PWi, JD, and EDA had full access to 
all the data in the study and had ﬁ nal responsibility for 
the decision to submit for publication. 
Results
Measurement of stored samples from 7129 participants 
(including 1173 incident cardiovascular disease cases) 
was done for eight prospective studies (the Reykjavik 
Oﬀ spring Study,23 the Northern Sweden Health and 
Disease Study,24 the Bruneck Study,25 and ﬁ ve cohorts 
contributing to the DAN-MONICA study;26 appendix 
p 3). We sought individual-participant data from 
33 relevant prospective studies. Only one potentially 
Articles
www.thelancet.com/diabetes-endocrinology   Vol 4   October 2016 843
relevant study27 (comprising <3% of the cardiovascular 
disease outcomes) was unable to contribute data, yielding 
a total of 40 contributing prospective studies from 
12 countries (of which 30 had been analysed as cohort 
studies, eight as case-cohort studies, and two as nested 
case-control studies) and 95 617 participants without a 
history of cardiovascular disease. Details of the 
40 contributing studies are provided in the appendix 
(pp 12, 17–20).12–16,23–26,28–51 
48 528 (51%) of participants were women and 61 451 
(64%) were from Europe, and mean age at baseline was 
61 years (SD 10). Median NT-proBNP concentration was 
64 pg/mL (IQR 30–135; appendix pp 19–20, 27). 
NT-proBNP concentrations were approximately linearly 
associated with BNP concentrations across the range 
of values (appendix p 28). NT-proBNP and BNP 
concentrations increased with age and were higher in 
women, but were only weakly associated with several 
other characteristics, including ethnicity, history of 
hypertension, use of antihypertensive medication, 
systolic blood pressure, total and HDL cholesterol 
concentration, and estimated glomerular ﬁ ltration rate 
(appendix pp 21, 22, 29).
During 809 525 person-years at risk (median follow-up 
7·8 years [IQR 5·2–11·8]), 5500 coronary heart disease, 
4002 stroke, and 2212 heart failure outcomes occurred. 
NT-proBNP concentration was non-linearly associated 
with the risk of each of these diseases (ﬁ gure 1). Risk 
ratios (top third vs bottom third of NT-proBNP 
concentration) adjusted for conventional risk factors 
were 1·76 (95% CI 1·56–1·98) for the combination of 
coronary heart disease and stroke; 2·00 (1·77–2·26) for 
the combination of coronary heart disease, stroke, and 
heart failure; 1·67 (1·45–1·93) for coronary heart disease; 
1·81 (1·58–2·07) for stroke; 3·45 (2·66–4·46) for heart 
failure; and 3·11 (2·34–4·15) for cardiovascular disease 
deaths due to additional causes (ﬁ gure 2; appendix p 30). 
Risk ratios were somewhat higher for fatal than for non-
fatal coronary heart disease (p<0·0001), but similar for 
ischaemic and haemorrhagic stroke (p=0·44). In the 
same participants, corresponding risk ratios with lower 
HDL cholesterol concentration were 1·61 (1·45–1·78) for 
the combination of coronary heart disease and stroke and 
1·47 (1·31–1·66) for the combination of coronary heart 
disease, stroke, and heart failure.
Risk ratios for NT-proBNP concentration did not 
materially change with further adjustment for body-
mass index or estimated glomerular ﬁ ltration rate, but 
they reduced somewhat with adjustment for CRP con-
centration (appendix p 23). Risk ratios for heart failure 
were higher in men than in women (4·25 vs 2·44; 
p<0·0001), in participants with a low body-mass index 
than a high body-mass index (3·61 vs 2·76; p=0·0004), 
and in studies that had stored samples for 10 years or 
fewer before analysis than longer than 10 years (6·20 vs 
2·68; p=0·0018; appendix p 31–32). Otherwise, risk 
ratios did not vary substantially with levels of 
conventional risk factors or in other clinically relevant 
subgroups (appendix pp 31–32). We observed 
qualitatively similar ﬁ ndings in analyses that deﬁ ned 
thirds separately for men and women, excluded people 
with high baseline con centrations of NT-proBNP, 
excluded the initial 5 years of follow-up, and were 
restricted to studies recording both fatal and non-fatal 
outcomes (appendix p 33). Similar ﬁ ndings were also 
noted in analyses that compared studies grouped by 
NT-proBNP concentration assay type or generation 
(appendix p 32), compared studies with diﬀ erent lengths 
of follow-up (appendix p 34), used per one SD higher log 
Figure 1: Associations of NT-proBNP and HDL-C concentrations with 
ﬁ rst-onset coronary heart disease, stroke, and heart failure
Risk ratios adjusted for age, smoking status, history of diabetes, systolic blood 
pressure, and total cholesterol and HDL-C concentration (HDL-C concentration 
only for NT-proBNP concentration analysis) and stratiﬁ ed by sex. Analyses 
involved 4716 coronary heart disease outcomes (from 34 cohorts), 3768 stroke 
outcomes (from 30 cohorts), and 2021 heart failure outcomes (from 16 cohorts). 
The size of the circles is proportional to the inverse of the variance of the 
respective estimate. Error bars are 95% CIs, estimated from ﬂ oated variances. 
HDL-C=HDL cholesterol. NT-proBNP=N-terminal-pro-B-type natriuretic peptide.
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NT-proBNP concentration (appendix p 24), and focused 
on fatal outcomes only (appendix p 35). In analyses of 
15 909 participants for coronary heart disease and stroke 
and 12 202 participants for heart failure from seven 
studies with available information about BNP 
concentration,28–34 risk ratios for coronary heart disease, 
stroke, and heart failure observed with BNP 
concentration were weaker than were those observed 
with NT-proBNP concentration (appendix p 25). We 
noted moderate heterogeneity of risk ratios across 
1 2 4
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Figure 2: Associations of NT-proBNP and HDL-C concentrations with several incident ﬁ rst-onset cardiovascular outcomes
Risk ratios adjusted for age, smoking status, history of diabetes, systolic blood pressure, and total cholesterol and HDL-C concentration (HDL-C concentration only for 
NT-proBNP concentration analysis) and stratiﬁ ed by sex. HDL-C=HDL cholesterol. NT-proBNP=N-terminal-pro-B-type natriuretic peptide. *Top versus bottom third 
of NT-proBNP concentration. †Bottom versus top third of HDL-C concentration. ‡Subsumes deaths due to cardiac arrhythmia, hypertensive disease, pulmonary 
embolism, complications and ill deﬁ ned descriptions of heart disease, sudden death, aortic aneurysms, and peripheral vascular disease.
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Figure 3: Improvement in risk discrimination for ﬁ rst-onset individual and composite cardiovascular disease outcomes by addition of information about 
NT-proBNP concentration compared with that about HDL-C concentration
Analyses involved 8323 outcomes for the combination of coronary heart disease plus stroke (from 32 cohorts), 6582 outcomes for the combination of coronary 
heart disease plus stroke plus heart failure (from 22 cohorts), 4552 coronary heart disease outcomes (from 32 cohorts), 3768 stroke outcomes (from 30 cohorts), 
and 2021 heart failure outcomes (from 16 cohorts). HDL-C=HDL cholesterol. NT-proBNP=N-terminal-pro-B-type natriuretic peptide. *The reference model included 
information about age, sex, smoking, systolic blood pressure, history of diabetes, and concentration of total cholesterol. 
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studies (appendix p 30). I² values were 45% for coronary 
heart disease, 23% for stroke, and 54% for heart failure.
After addition of NT-proBNP concentration to a model 
with conventional risk factors only, the C-index 
increased by 0·012 (95% CI 0·010–0·014) for the 
combination of coronary heart disease and stroke; 0·019 
(0·016–0·022) for the combination of coronary heart 
disease, stroke, and heart failure; 0·012 (0·009–0·015) 
for coronary heart disease; 0·011 (0·008–0·015) for 
stroke; and 0·038 (0·030–0·045) for heart failure 
(ﬁ gure 3; appendix pp 36–37). Overall net reclassiﬁ cation 
improvements for NT-proBNP concentration across 
predicted 10 year risk categories deﬁ ned by the 2013 
ACC and AHA guidelines1 were 0·027 (0·019–0·036) 
for the combination of coronary heart disease and stroke 
and 0·028 (0·019–0·038) for the combination of 
coronary heart disease, stroke, and heart failure (table). 
Continuous net reclassiﬁ cation improvements were 
0·154 (0·111–0·198) for the combination of coronary 
heart disease and stroke and 0·198 (0·162–0·234) for 
the combination of coronary heart disease, stroke, and 
heart failure, and integrated discrimination 
improvements were 0·013 (0·011–0·015) for the 
combination of coronary heart disease and stroke and 
0·030 (0·026–0·033) for the combination of coronary 
heart disease, stroke, and heart failure (appendix p 26). 
Incremental risk prediction aﬀ orded by NT-proBNP 
concentration assessment was greater than that aﬀ orded 
by HDL cholesterol or CRP concentration assessment 
(ﬁ gure 3, ﬁ gure 4, table). NT-proBNP and CRP 
concentration provided essentially non-overlapping 
incremental risk discrimination (ﬁ gure 4). 
In further analyses that involved the combination of 
coronary heart disease, stroke, and heart failure as the 
outcome, improvements in C-index with NT-proBNP 
concentration assessment were possibly greater among 
older individuals and people with a history of diabetes, 
who used antihypertensives, who had a higher systolic 
blood pressure, and who had a lower total cholesterol 
concentration (appendix p 38). However, we did not adjust 
these exploratory analyses for multiple com parisons. In 
further sensitivity analyses, we found that C-index 
improvements were similar when the base model 
additionally included information about ethnicity and 
antihypertensive treatment (appendix p 39), but somewhat 
smaller in analyses that excluded people with high baseline 
concentrations of NT-proBNP or modelled NT-proBNP 
concentration using a prespeciﬁ ed cutoﬀ  value rather than 
continuous values (appendix p 40). Net reclassiﬁ cation 
improvements were similar or larger than were those in 
the main analysis when analysis involved cutoﬀ s for 
clinical risk categories deﬁ ned by guidelines other than the 
2013 ACC and AHA guidelines1 (appendix p 26). 
Discussion
In this study, we found that NT-proBNP concentration 
assessment strongly predicted ﬁ rst-onset heart failure 
and augmented coronary heart disease and stroke 
prediction, suggesting that NT-proBNP concentration 
assessment could serve as a multipurpose biomarker in 
new approaches that integrate heart failure into 
cardiovascular disease primary prevention. A key 
observation was our study’s demonstration of graded 
associations between NT-proBNP concentration and the 
incidence of coronary heart disease, stroke, and heart 
failure. The continuous nature of these associations 
suggests that NT-proBNP concentration measurement 
is potentially suitable for population-level risk 
assessment. We also made the surprising observation 
that NT-proBNP concentration predicts stroke at least as 
strongly as it does coronary heart disease, by contrast 
with the idea that NT-proBNP concentration is 
predominantly a coronary biomarker. The stroke 
associations that we noted could partly be explained by 
associations previously reported between NT-proBNP 
concentration and stroke risk factors (eg, left ventricular 
hypertrophy and atrial ﬁ brillation),15,52 but further work 
is needed to elucidate the common pathobiology for 
coronary heart disease, stroke, and heart failure reﬂ ected 
by preceding NT-proBNP concentration. Furthermore, 
we found that NT-proBNP concentration predicted 
deaths due to additional cardiovascular causes, such as 
cardiac arrhythmia and sudden death.53 Collectively, 
these results encourage evaluation of NT-proBNP 
concentration for prediction of an even wider range of 
cardiovascular disease outcomes than that we studied.
Non-cases Cases Overall
Coronary heart disease plus stroke
Conventional risk factors without 
HDL-C concentration*
Reference Reference Reference
plus HDL-C concentration 0·001 
(–0·003 to 0·004); 
p=0·70
0·008 
(–0·000 to 0·016); 
p=0·056
0·009 
(–0·000 to 0·017); 
p=0·056
plus HDL-C and NT-proBNP 
concentration
0·029 
(0·025 to 0·032); 
p<0·0001
–0·001 
(–0·009 to 0·007); 
p=0·79
0·027 
(0·019 to 0·036); 
p<0·0001
Coronary heart disease plus stroke plus heart failure
Conventional risk factors without 
HDL-C concentration*
Reference Reference Reference
plus HDL-C concentration 0·011 
(0·008 to 0·015); 
p<0·0001
0·006 
(–0·001 to 0·013); 
p=0·10
0·017 
(0·009 to 0·025); 
p<0·0001
plus HDL-C and NT-proBNP 
concentration
0·036 
(0·032 to 0·040); 
p<0·0001
–0·008 
(–0·017 to 0·001); 
p=0·087
0·028 
(0·019 to 0·038); 
p<0·0001
Data are categorical net reclassiﬁ cation improvement versus preceding model (95% CI); p value. We calculated 
categorical net reclassiﬁ cation improvement across predicted 10 year cardiovascular disease risk categories deﬁ ned 
by the American College of Cardiology and American Heart Association 2013 guidelines.1 Analyses involved 
4672 outcomes for the composite outcome of coronary heart disease plus stroke (from 19 cohorts) and 4071 for the 
composite outcome of coronary heart disease plus stroke plus heart failure (from 16 cohorts). HDL-C=HDL cholesterol. 
NT-proBNP=N-terminal-pro-B-type natriuretic peptide. *The reference model included information about age, sex, 
smoking, systolic blood pressure, history of diabetes, and concentration of total cholesterol. 
Table: Improvement in risk classiﬁ cation for ﬁ rst-onset composite cardiovascular disease outcomes by 
addition of information about NT-proBNP concentration compare d with that about HDL-C
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Our conclusions on the incremental predictive ability 
of assessment of NT-proBNP concentration were 
strengthened by broadly concordant results when we 
studied varying cardiovascular disease outcomes and 
used diﬀ erent measures of risk discrimination and 
reclassiﬁ cation. Importantly, the modest improvements 
that we observed in risk reclassiﬁ cation with NT-proBNP 
concentration assessment applied similarly across the 
absolute risk thresholds used in diﬀ erent clinical 
guidelines.1–4 In particular, NT-proBNP concentration 
assessment improved the speciﬁ city of risk prediction by 
appropriately downclassifying the clinical risk category of 
many individuals who did not go on to develop 
cardiovascular disease outcomes. Hence, addition of 
NT-proBNP concentration measurement to cardiovascular 
disease risk assessment could improve targeting of 
preventive treatments (such as statins) and allocation of 
resources for detailed screening (such as comprehensive 
tests for heart failure at specialised cardiology clinics), as 
exempliﬁ ed by previous natriuretic peptide-guided trials 
in patients with diabetes54 or heart failure.55,56 Data from 
future studies are needed to establish the cost-
eﬀ ectiveness and feasibility of NT-proBNP concentration 
screening for prediction of ﬁ rst composite cardiovascular 
disease outcomes, analogous with previous work on left 
ventricular systolic dysfunction.57–59
To provide clinical context, we compared incremental 
improvements aﬀ orded by NT-proBNP concentration 
assessment with those aﬀ orded by HDL cholesterol, a 
widely used biomarker in cardiovascular disease risk 
assessment (this comparison is additionally relevant 
because HDL cholesterol concentration, like NT-proBNP 
concentration, is a biomarker of unknown relevance to 
the cause of cardiovascular disease60). We found that 
improvements in risk discrimination with NT-proBNP 
concentration were greater than those provided by HDL 
cholesterol, even though our evaluation was skewed in 
favour of HDL cholesterol concentration since we added 
HDL cholesterol concentration only to other conventional 
risk factors (omitting NT-proBNP concentration), 
whereas we added NT-proBNP concentration to 
conventional risk factors, including HDL cholesterol 
concentration. Furthermore, in a head-to-head 
comparison, we found that the improvement in risk 
discrimination with NT-proBNP concentration was about 
three times greater than was the improvement in risk 
discrimination using CRP concentration. The idea that 
NT-proBNP concentration captures information about 
non-traditional cardiovascular disease pathways61,62 was 
supported by our observation that NT-proBNP 
concentration was uncorrelated or weakly correlated with 
the established and emerging risk factors that we studied.
Our study had major strengths. Because of its 
considerable statistical power, we could provide precise 
estimates, even for analyses that involved categorisation 
of NT-proBNP concentrations. More than 90% of the 
NT-proBNP concentration data in our analysis were 
generated with use of a common gold-standard assay. We 
Figure 4: Improvement in risk discrimination for ﬁ rst-onset individual and composite cardiovascular outcomes by addition of information about CRP and 
NT-proBNP concentration to a model with conventional risk factors
Analyses involved 7618 outcomes for the combination of coronary heart disease plus stroke (from 28 cohorts), 5492 outcomes for the combination of coronary 
heart disease plus stroke plus heart failure (from 18 cohorts), 4120 coronary heart disease outcomes (from 27 cohorts), 3487 stroke outcomes (from 26 cohorts), 
and 1606 heart failure outcomes (from 13 cohorts). CRP=C-reactive protein. NT-proBNP=N-terminal-pro-B-type natriuretic peptide. *The reference model included 
information about age, sex, smoking, systolic blood pressure, history of diabetes, and concentrations of total and HDL cholesterol. 
0 0·01 0·02 0·03 0·04 0·05 0·06
Coronary heart disease plus stroke
Conventional risk factors*
Coronary heart disease
Conventional risk factors*
plus CRP concentration
plus NT-proBNP concentration
plus CRP concentration
plus NT-proBNP concentration
plus CRP concentration
plus NT-proBNP concentration
plus CRP concentration
plus NT-proBNP concentration
plus CRP concentration
plus NT-proBNP concentration
Stroke
Conventional risk factors*
Coronary heart disease plus stroke plus heart failure
Conventional risk factors*
Heart failure
Conventional risk factors*
Individual outcomes
Composite outcomes
Reference
0·004 (0·002 to 0·005)  0·0003
0·011 (0·009 to 0·014)  <0·0001
Reference
0·005 (0·002 to 0·007)    0·0002
0·012 (0·008 to 0·015)  <0·0001
Reference
0·002 (–0·000 to 0·005)  0·05
0·011 (0·007 to 0·015)  <0·0001
Reference
0·007 (0·005 to 0·009)  <0·0001
0·020 (0·017 to 0·024)  <0·0001
Reference
0·015 (0·009 to 0·020)  <0·0001
0·045 (0·036 to 0·055)  <0·0001
0·660 (0·654 to 0·666)
0·664 (0·657 to 0·670)
0·672 (0·665 to 0·678)
0·669 (0·661 to 0·677)
0·673 (0·665 to 0·681)
0·681 (0·672 to 0·689)
0·659 (0·650 to 0·668)
0·662 (0·653 to 0·671)
0·670 (0·661 to 0·679)
0·698 (0·691 to 0·705)
0·705 (0·698 to 0·712)
0·718 (0·711 to 0·725)
0·720 (0·708 to 0·732)
0·735 (0·723 to 0·747)
0·765 (0·753 to 0·777)
C-index change (95% CI)
versus reference model
C-index (95% CI) p value
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recorded information about the incidence of various 
cardiovascular disease outcomes using well validated 
endpoint deﬁ nitions. We centrally analysed individual-
participant data, which were harmonised from prospective 
studies with extended follow-up, enabling time-to-event 
analyses, exclusion of people with a baseline history of 
cardiovascular disease (including heart failure), and 
adoption of a uniform approach to statistical analyses. To 
enhance validity further, we restricted analyses to people 
with complete information about a set of relevant risk 
factors. Our primary analysis excluded participants with a 
reported baseline history of heart failure and, moreover, 
the ﬁ ndings were robust to exclusion of participants with 
high baseline NT-proBNP concentrations. The 
generalisability of our ﬁ ndings was enhanced by inclusion 
of data from 12 countries and by the robustness of results 
to various sensitivity analyses.
Our study had potential limitations. Misclassiﬁ cation of 
heart failure outcomes could have led to underestimation 
of associations between NT-proBNP concentration and 
heart failure risk and, conversely, overestimation of 
associations with non-heart failure outcomes. Most of our 
data were derived from people of European continental 
ancestry. We could not compare the performance of NT-
proBNP concentration with cardiac troponin, coronary 
calcium scoring, or other biomarkers apart from HDL 
cholesterol and CRP concentrations.
We conclude that assessment of NT-proBNP 
concentration could serve as a multipurpose biomarker 
in new approaches that integrate heart failure into 
primary prevention of cardiovascular diseases.
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